Venous thromboembolism prophylaxis conversion in nonsurgical inpatients

Annals of Pharmacotherapy

Volumn 37, Issue 9, 2003, Pages 1194-1196

  Carroll, Douglas N ^a   Hudson, Edward B ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b Hillcrest Medical Center   (United States)

Author keywords

Heparin; Low molecular weight heparin; Prophylaxis; Venous thromboembolism

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVALUATION; FOLLOW UP; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOEMBOLISM; TREATMENT PLANNING; VEIN THROMBOSIS;

ANTICOAGULANTS; COST-BENEFIT ANALYSIS; ENOXAPARIN; HEMORRHAGE; HEPARIN; HOSPITALIZATION; HUMANS; RISK FACTORS; THERAPEUTIC EQUIVALENCY; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0042424795     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C509     Document Type: Article

References (9)

1. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991;151:933-8.
2. Tapson VF. Prophylaxis strategies for patients with acute venous thromboembolism. Am J Managed Care 2001;7(17 suppl):S524-34.
3. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl 1):132S-75S.
4. Bergmann JF, Elkharrat D. Prevention of venous thromboembolic risk in non-surgical patients. Haemostasis 1996;26(suppl 2):16-23.
5. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of VTE. Ann Intern Med 1991;115:591-5.
6. Bratzler DW, Raskob GE, Murray CK, Bumpus LJ, Piatt DS. Underuse of VTE prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med 1998;158:1909-12.
7. Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 1996; 26(suppl 2): 49-56.
8. Kleber FX, Witt C, Flosbach CW, Koppenhagen K, Vogel G. Study to compare the efficacy and safety of the LMWH enoxaparin and standard heparin in the prevention of thromboembolic events in medical patients with cardiopulmonary diseases (abstract). Ann Hematol 1998;76(suppl 1):P261.
9. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a metaanalysis of randomized clinical trials. Thromb Haemost 2000;83:14-9.